Loading…
Budgeting for Opioid Addiction Treatment Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
37pct
1d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Budgeting for Opioid Addiction Treatment Act This bill amends the Internal Revenue Code, with respect to excise taxes on manufacturers, to impose a one cent per milligram fee on the sale of active opioids by the manufacturer, producer, or importer. The fee excludes prescription drugs used exclusively for the treatment of opioid addiction as part of a medically assisted treatment effort. The Department of Health and Human Services (HHS) must establish a program to provide rebates or discounts to cancer and hospice patients to ensure that they do not pay the fee. The bill amends the Public Health Service Act to require any increase in federal revenues from the fee after rebates and discounts are subtracted to be distributed to states under the Substance Abuse Prevention and Treatment Block Grant program. The states must use the funds exclusively for substance abuse (including opioid abuse) efforts in the states, including: (1) specified treatment programs, and (2) the recruitment and training of substance use disorder professionals to work in rural and medically underserved communities. HHS must report to Congress on the impact of this bill on the retail cost of opioids and patient access to opioid medication, the effectiveness of the discount or rebate for cancer and hospice patients, how the funds are being used to improve substance abuse treatment efforts, and suggestions for improving access to opioids for cancer and hospice patients and substance abuse treatment efforts.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2018 · third_quarter · Health Issues
Monitor and advocate on legislative and regulatory issues regarding healthcare. H.R. 6, SUPPORT for Patients and Communities Act. H.R. 541, Improving Oversight and Accountability in Medicaid Non-DSH Supplemental Payments Act. H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R. 2038, Budgeting for Opioid Addiction Treatment Act. H.R. 2843, Medicaid and CHIP Quality Improvement Act of 2017. H.R. 5795, Overdose Prevention and Patient Safety Act. H.R. 5797, Individuals in Medicaid Deserve Care that is Appropriate and Responsible in its Execution Act. H.R. 6071, SERV Communities Act. H.R. 6082, Overdose Prevention and Patient Safety Act. H.R. 6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 H.R. 6470, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019. H.R. 6733, Know the Cost Act of 2018. S.413, Improving Transparency and Accuracy in Medicare Part D Spending Act. S. 523, Budgeting for Opioid Addiction Treatment Act. S. 1079, Protecting Americans from Dangerous Opioids Act. S. 1123, Office of National Drug Control Policy Reauthorization Act of 2017. S. 2553, Know the Lowest Price Act of 2018. S. 2554, Patient Right to Know Drug Prices Act. S. 2680, Opioid Crisis Response Act of 2018. S. 3120, HEAL Act of 2018.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress.gov source codes: H11100, H11100-A
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
Monitor and advocate on legislative and regulatory issues regarding healthcare. H.R. 6, SUPPORT for Patients and Communities Act. H.R. 541, Improving Oversight and Accountability in Medicaid Non-DSH Supplemental Payments Act. H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R. 2038, Budgeting for Opioid Addiction Treatment Act. H.R. 2843, Medicaid and CHIP Quality Improvement Act of 2017. H.R. 2851, SITSA Act. H.R. 4392, To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes. H.R. 4710, 340B PAUSE Act. H.R. 5795, Overdose Prevention and Patient Safety Act. H.R. 5797, Individuals in Medicaid Deserve Care that is Appropriate and Responsible in its Execution Act. H.R. 6082, Overdose Prevention and Patient Safety Act. S. 155, RAISE Act. S.413, Improving Transparency and Accuracy in Medicare Part D Spending Act. S. 523, Budgeting for Opioid Addiction Treatment Act. S. 1079, Protecting Americans from Dangerous Opioids Act. S. 1123, Office of National Drug Control Policy Reauthorization Act of 2017. S. 1317, Medicaid and CHIP Quality Improvement Act of 2017. S. 2453, Ensuring the Value of the 340B Program Act of 2018. S. 2680, Opioid Crisis Response Act of 2018.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES
2018 · first_quarter · Health Issues
Monitor and advocate on legislative and regulatory issues regarding healthcare. H.R. 1892, Bipartisan Budget Act of 2018 (P.L. 115-123). H.R. 1625, Consolidated Omnibus Appropriations 2018 (P.L. 115-124). H.R. 195, Extension of Continuing Appropriations Act, 2018 (P.L. 115-120). H.R. 1301, Continuing Appropriations Amendments Act, 2018 (P.L. 115-124). H.R. 601, Continuing Appropriations Act, 2018 and Supplemental Appropriations for Disaster Relief Requirements Act, 2017 (P.L. 115-56). H.R. 1370, Further Additional Continuing Appropriations Act, 2018 (P.L. 115-96). S.413, Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R. 541, Improving Oversight and Accountability in Medicaid Non-DSH Supplemental Payments Act. S. 1079, Protecting Americans from Dangerous Opioids Act. H.R. 2038, Budgeting for Opioid Addiction Treatment Act. S. 523, Budgeting for Opioid Addiction Treatment Act. H.R. 2843, Medicaid and CHIP Quality Improvement Act of 2017. S. 1317, Medicaid and CHIP Quality Improvement Act of 2017. H.R. 4392, To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes. H.R. 4710, 340B PAUSE Act. S. 2453, Ensuring the Value of the 340B Program Act of 2018.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES